Pharmacokinetics of the gonadotrophin inhibitor 19 beta-cis-ethyliden-17 alpha-ethynyl-17 beta-hydroxy-androstatrien-3-one (Ro 6-5403) in man.
D000284:Administration, Oral; D000328:Adult; D000737:Androstenols / Q000008:administration & dosage / Q000378:metabolism*; D001702:Biopharmaceutics; D001711:Biotransformation; D002855:Chromatography, Thin Layer; D005260:Female; D006062:Gonadotropins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006207:Half-Life; D006801:Humans; D007275:Injections, Intravenous; D007664:Ketosteroids / Q000008:administration & dosage / Q000378:metabolism; D007700:Kinetics; D008433:Mathematics; D009651:Norpregnatrienes; D013997:Time Factors; D014316:Tritium
D000737:Androstenols; D006062:Gonadotropins; D007664:Ketosteroids; D009651:Norpregnatrienes; D014316:Tritium; C007676:Ro 6-5403